Efficacy Evaluation of Shen Cao Gan Jiang Tang on Mild and Moderate COVID-19 Patients
Status:
Recruiting
Trial end date:
2022-08-20
Target enrollment:
Participant gender:
Summary
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the virus that causes
COVID-19 (coronavirus disease 2019). Patients with COVID-19 may experience various clinical
manifestations, from no symptoms to critical illness such as severe pneumonia and acute
respiratory distress syndrome (ADRS). So far, there is no specific medication for COVID-19;
hence, the current available treatments mostly aim at symptoms management and supportive
care. From traditional medicine perspective, COVID-19 is classified as warm-disease (Wen-yi).
The main points of treatment for COVID-19 in early stage based on traditional medicine
perspective are strengthen the Protective Qi (Wei Qi - the body immune system), and restore
the balance of Qi, which is vital biological energy to prevent the invasion of external
pathogens, including the SARS-CoV-2 virus. The Shen Cao Gan Jiang Tang have including Gan Cao
Gan Jiang Tang (GGT) with the addition of Ginseng. This formula is originated from Shang Han
Lun (Treatise on Febrile Diseases Caused by Cold) by Zhang Zhong-jing, used to enhance the
Protective Qi, treat the early stage of Febrile Diseases, This clinical trial aims to
evaluate the efficacy of the Shen Cao Gan Jiang Tang on mild and moderate COVID-19 patients
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
University of Medicine and Pharmacy at Ho Chi Minh City